Axamon, solution Ampoules 15mg/ml 1ml 10pcs

Composition

Solution for intramuscular and subcutaneous use 1 ml

Active ingredient:  

Ipidacrine hydrochloride monohydrate (in terms of anhydrous) 15 mgsupport substances:

0.1 M hydrochloric acid solution-up to pH 3;

water for injection – up to 1 ml

Pharmacological action

Axamon® is a reversible cholinesterase inhibitor that directly stimulates impulse conduction in the neuromuscular synapse and in the central nervous system (CNS) due to the blockade of the potassium channels of the membrane. Increases the effect on smooth muscles of not only acetylcholine, but also epinephrine, serotonin, histamine and oxytocin.

Axamon® has the following pharmacological effects:

– improves and stimulate impulse conduction in the nervous system and neuromuscular transmission;- improves the conductivity in the peripheral nervous system, impaired due to injury, inflammation, effects of local anesthetics, some antibiotics, potassium chloride, etc. ; – increases the contractility of smooth muscle organs under the influence of agonists acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, with the exception of potassium chloride;- improves memory, progradient inhibits the development of dementia.

It has no teratogenic, embryotoxic, mutagenic, carcinogenic or immunotoxic effects. It does not affect the endocrine system.

Pharmacokinetics

When administered subcutaneously and intramuscularly, it is rapidly absorbed. The maximum concentration in the blood is reached in 25-30 minutes after use. Binding to plasma proteins is 40-50%.

The drug quickly enters the tissues. It is metabolized in the liver. Excretion of the drug is carried out through the kidneys (mainly by tubular secretion and only 1/3 by glomerular filtration) and extrarenally (through the gastrointestinal tract).

The half-life of Axamon® with parenteral use is 2-3 hours. After parenteral use,34.8% of the drug dose is excreted unchanged in the urine.

Indications

-diseases of the peripheral nervous system: mono-and polyneuropathy, polyradiculopathies, myasthenia gravis and myasthenic syndrome of various etiologies—

– diseases of the central nervous system: bulbar paralysis and paresis, recovery period of organic lesions of the central nervous system, accompanied by motor disorders—

– intestinal atony.

Use during pregnancy and lactation

The use of the drug increases the tone of the uterus and can lead to premature birth, so ipidacrine is contraindicated during pregnancy. There are no data on the use

of the drug during breastfeeding.

Contraindications

-epilepsy; – extrapyramidal disorders with hyperkinesis;— angina pectoris; – severe bradycardia;— bronchial asthma;- mechanical obstruction of the bowel or urinary tract;- vestibular disorders;— peptic ulcer of the stomach or duodenum in the acute stage— – children under 18 years of age (there are no systematic data on the use in children);- hypersensitivity to any of the components of the drug. With caution, it is prescribed for peptic ulcer of the stomach and duodenum, thyrotoxicosis, diseases of the cardiovascular system, obstructive diseases of the respiratory system in the anamnesis or acute respiratory diseases.

Side effects

The frequency of adverse reactions that may occur during the use of the drug is given in the following classification: very frequent (>1/10 appointments), frequent (1/10-1/100 appointments), infrequent (1/100-1/1000 appointments), rare (1/1000-1/10 000 appointments), very rare (>

From the side of the psyche: infrequent-drowsiness.

From the nervous system: infrequent – dizziness, headache, convulsions; unknown frequency-tremor.

From the side of the organ of vision: unknown frequency-miosis.

From the heart: frequent – palpitations, bradycardia; unknown frequency-pain behind the sternum.

From the respiratory system: infrequent-increased secretion of bronchial secretions.

From the gastrointestinal tract: frequent-salivation, nausea; infrequent-vomiting; rare-diarrhea, epigastric pain.

From the liver and biliary tract: unknown frequency-jaundice.

Skin and subcutaneous tissue disorders: infrequent-pruritus, rash.

General disorders and disorders at the injection site: frequent-increased sweating; infrequent-general weakness; unknown frequency-hypothermia.

Salivation and bradycardia can be reduced with m-holinoblockers (including atropine, cyclodol, metacin).

If itching or rash occurs, stop taking the drug. In other cases, reduce the dose or stop taking the drug for a short time (for 1-2 days).

Interaction

The risk of developing bradycardia increases if beta-blockers were used before starting treatment with Axamon®.

Weakens the inhibitory effect of local anesthetics, aminoglycosides, potassium chloride on neuromuscular transmission and conduction of excitation along peripheral nerves.

Axamon® can be used in combination with nootropic drugs.

Ethanol increases the side effects of the drug.

How to take, course of use and dosage

The drug is administered subcutaneously or intravenously. The dose and duration of treatment are determined individually, depending on the severity of the disease. Diseases of the peripheral nervous system

Mono-and polyneuropathies of various origins, polyradiculopathies: subcutaneous or intravenous 5-15 mg 1-2 times a day, a course of 10-15 days (in severe cases-up to 30 days); then treatment is continued with the tablet form of the drug.

Myasthenia gravis and myasthenic syndrome: subcutaneous or intravenous use of 15-30 mg 1-3 times a day with further transition to tablet form. The general course of treatment is 1-2 months. If necessary, the treatment can be repeated several times with a break between courses of 1-2 months.

CNS diseases:

Bulbar paralysis and paresis: subcutaneous or intravenous use of 5-15 mg 1-2 times / day, a course of 10-15 days; then, if possible, switch to the tablet form;Recovery period of organic CNS lesions accompanied by motor disorders: i / m 10-15 mg 1-2 times/day, a course of up to 15 days; then, if possible, switch to the tablet form.

Treatment and prevention of intestinal atony: the initial dose is 10-15 mg 1-2 times / day for 1-2 weeks.

Overdose

Symptoms: decreased appetite, bronchospasm, lacrimation, increased sweating, pupil constriction, nystagmus, increased gastrointestinal motility, spontaneous defecation and urination, vomiting, jaundice, bradycardia, impaired intracardiac conduction, arrhythmias, decreased blood pressure, anxiety, anxiety, agitation, fear, ataxia, convulsions, coma, speech disorders, drowsiness and general weakness.

Treatment: use of m-holinoblokatorov (including atropine, cyclodol, metacin), symptomatic therapy.

Special instructions

Influence on the ability to drive motor vehicles and manage mechanisms

During treatment, you should refrain from driving a car, other vehicles and mechanisms, as well as from engaging in potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Product form

solution for intramuscular and subcutaneous use

Storage conditions

In a dark place, at a temperature not exceeding 25 °C

Shelf life

2 years

Active ingredient

Ipidacrine

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection

Description

For adults as directed by your doctor

Indications

Polyneuropathy, Stroke Effects, Alzheimer ‘s Disease